DS
PSTX

David Shaw’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

David Shaw’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,173
Closed -$47.8K – 4556
2023
Q2 		$47.8K Sell
27,173
-58,456
-68% -$149K ﹤0.01% 3882
2023
Q1 		$264K Sell
85,629
-253,492
-75% -$1.52M ﹤0.01% 3797
2022
Q4 		$1.8M Buy
339,121
+143,237
+73% +$655K ﹤0.01% 3022
2022
Q3 		$691K Buy
+195,884
New +$648K ﹤0.01% 3841

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

David Shaw's PSTX Position: Q3 2023 in Review

David Shaw sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2023, closing a stake of 27,173 shares — an estimated $47.8K sold.

David Shaw first reported a position in PSTX in Q3 2022 and held it in 4 quarters. The position peaked at $1.8M in Q4 2022. 86 funds tracked by Wall St. Rank hold PSTX as of Q3 2023.

  • David Shaw reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • David Shaw sold 27,173 Poseida Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $47.8K.
  • David Shaw first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • David Shaw's Poseida Therapeutics, Inc. Common Stock position peaked at $1.8M in Q4 2022.
  • 86 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2023.

Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.